
Melanotan II
In tiny 1990s studies, melanotan II darkened the skin of 2 of 3 men and caused erections in 17 of 20 men with erectile dysfunction, with frequent nausea. It was never approved. Case reports describe melanoma, rapidly changing moles, priapism, muscle breakdown with kidney injury, kidney infarction and a brain swelling syndrome in people using products bought online. It is not the same as the approved drugs afamelanotide (Scenesse) or bremelanotide (Vyleesi).
Research compound: not an approved drug or dietary supplement
This compound is sold for research and is not FDA-approved for human use or as a dietary supplement. Human evidence is limited; purity and dosing of consumer products are unverified. The data below is an evidence review for education only. Talk to a clinician before considering it.
Quick decision guide
May help most
No approved use; research participants in registered trials only
Common dosing range
No approved or established dose. 1990s trials used 0.025 mg per kg injected under the skin under supervision
When to expect effects
Erections began within hours of an injection in trials; skin darkening was measured a week after 5 doses
Watch out for
Not FDA-approved; FDA cites case reports of melanoma, PRES, sympathomimetic toxidrome and priapism; case reports describe darkened and new moles, which can make skin cancer harder to spot; online products are unverified
What is it
Melanotan II (MT-II) is a lab-made peptide that copies alpha-melanocyte stimulating hormone (alpha-MSH), the body's own signal for skin pigment. It was tested in a few small studies in the 1990s and then never developed into an approved drug, but it is sold online as injections and nasal sprays for tanning and sexual arousal. It is not FDA-approved for any use. It is often confused with two different, approved medicines that act on the same family of receptors: afamelanotide (Scenesse) is an implant placed under the skin by a health professional, approved to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria, a rare light-sensitivity disease; bremelanotide (Vyleesi) is an injection approved for acquired, generalized low sexual desire (HSDD) in premenopausal women. Melanotan II is neither of them. FDA's compounding safety page lists melanotan II among bulk substances previously in category 2 (substances that may present significant safety risks) whose nominations were withdrawn by the nominators, and says published case reports discuss serious adverse events including melanoma, a brain swelling syndrome (PRES), sympathomimetic toxidrome and priapism. Separately, an FDA early announcement says its Pharmacy Compounding Advisory Committee will discuss melanotan II, among bulk substances being considered for inclusion on the 503A bulks list, at a meeting FDA will host before the end of February 2027 (date not yet set). A phase 2 trial of melanotan II with light therapy for vitiligo is registered and recruiting.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
erections in men with erectile dysfunction Limited Evidence | 17 of 20 men had erections; about 38 to 45 minutes of strong rigidity versus 2 to 3 minutes on placebo | Research participants only | Within the 6-hour monitoring period after an injection |
skin darkening (tanning) Mixed Evidence | Measurable darkening in 2 of 3 men | Research participants only | Seen one week after 5 doses |
erections in men with erectile dysfunction
- Effect
- 17 of 20 men had erections; about 38 to 45 minutes of strong rigidity versus 2 to 3 minutes on placebo
- Best fit
- Research participants only
- Time
- Within the 6-hour monitoring period after an injection
skin darkening (tanning)
- Effect
- Measurable darkening in 2 of 3 men
- Best fit
- Research participants only
- Time
- Seen one week after 5 doses
Evidence for 2 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
erections in men with erectile dysfunction
Disease adjunctTwo small double-blind, placebo-controlled crossover trials from one US group tested 0.025 mg per kg injected under the skin. In 10 men with psychogenic erectile dysfunction, 8 developed erections; the time with tip rigidity above 80% averaged 38.0 minutes versus 3.0 on placebo (p = 0.0045). In 10 men with organic risk factors, erections followed 12 of 19 injections versus 1 of 21 placebo doses (45.3 versus 1.9 minutes of rigidity, P = 0.047), and sexual desire scores were higher. Across both, 17 of 20 men had erections, but nausea and yawning were frequent: the authors reported severe nausea in 12.9% at this dose, and after 4 of 19 injections in the organic group. The trials tested at most two doses per man, and the drug was never developed further for this use.
Bottom line: It caused erections in tiny 1990s trials, with frequent nausea, and was never approved.
skin darkening (tanning)
Biomarker supportIn a single-blind, placebo-controlled pilot phase 1 study of 3 healthy men, injections under the skin on alternate weekdays for 2 weeks (5 doses, 0.01 to 0.03 mg per kg) increased pigmentation of the face, upper body and buttocks in 2 men, measured by reflectance one week after the last dose. Nausea was reported at most doses, and erections occurred for 1 to 5 hours after dosing. No study has tested whether this tan protects against sunburn or skin cancer, and case reports describe new and darkened moles and melanoma in users.
Bottom line: It can darken skin, but no study shows the tan is protective, and mole changes and melanoma have been reported.
How it works
How to take it
What to track
Bottom line: No approved dose exists; the products sold online are unverified and have been linked to serious harm.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Melanoma and changing moles. Case reports describe melanoma in a 20-year-old woman 3 months after a 3 to 4 week course combined with sunbeds, melanoma in situ after melanotan use, a mucosal melanoma in the mouth of a 22-year-old woman who used a melanotan II nasal spray, and new and darkened moles within 24 hours of a single injection. FDA's compounding safety summary also names melanoma. Case reports cannot prove cause, but darkened moles can make skin cancer harder to spot.
Sympathomimetic toxicity and muscle breakdown (rhabdomyolysis). A 39-year-old man who injected 6 mg bought online developed a heart rate up to 146, sweating, tremor and agitation, with creatine kinase peaking at 17,773 IU/L and kidney injury; he needed intensive care. Laboratory testing confirmed melanotan II. Another case report described kidney infarction (loss of blood flow to part of a kidney) that its authors attributed most likely to melanotan II.
Priapism (a painful erection that will not go away). A case report described low-flow priapism after an injection of melanotan (the report does not say which form), treated by draining the penis; erectile function had not recovered 4 weeks later.
Posterior reversible encephalopathy syndrome (PRES), a brain swelling syndrome that can cause headache, confusion, vision loss and seizures, has been described in a published case report linked to melanotan use, and FDA's compounding safety summary names PRES.
Unverified products and immune reactions. FDA says compounded melanotan II may pose a risk of immune reactions for certain routes due to the potential for aggregation or peptide-related impurities. Products bought online have no verified content or dose. FDA's Pharmacy Compounding Advisory Committee is due to discuss melanotan II at a meeting before the end of February 2027; until then no compounded or other melanotan II product has FDA review.
Who should avoid it
- People with many moles, a history of melanoma or other skin cancer, or a family history of melanoma
- People with heart disease, high blood pressure or kidney disease: a case report described a racing heart, muscle breakdown and kidney injury, and another described kidney infarction
- Men with a history of priapism
- Anyone outside a supervised clinical trial: it is not approved for any use, and FDA cites serious adverse events in published case reports
Pregnancy & breastfeeding
There are no human data on melanotan II in pregnancy or breastfeeding: the published trials enrolled men only. Ask your doctor before any use if you are pregnant, breastfeeding or planning a pregnancy.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is melanotan II FDA-approved?⌄
No. Melanotan II is not approved for any use in the US. FDA's compounding safety page lists it among bulk substances previously in category 2 (substances that may present significant safety risks) whose nominations were withdrawn by the nominators. Separately, an FDA early announcement says its Pharmacy Compounding Advisory Committee will discuss melanotan II, among substances being considered for the 503A bulks list, at a meeting before the end of February 2027. A phase 2 vitiligo trial is registered and recruiting.
Is melanotan II the same as Scenesse or Vyleesi?⌄
No. Afamelanotide (Scenesse) is an FDA-approved implant that increases pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. Bremelanotide (Vyleesi) is an FDA-approved injection for acquired, generalized low sexual desire in premenopausal women. Both act on melanocortin receptors, like melanotan II, but they are different molecules with their own trials, labels and safety monitoring. Melanotan II is neither.
Does melanotan II cause skin cancer?⌄
It has not been proven to cause it, but melanoma has been reported in several users, and one case report described new and darkened moles 24 hours after a single injection. Darker moles can make changes harder to spot. FDA's safety summary lists melanoma among serious adverse events in case reports. If you have used it, have your skin checked by a dermatologist.
Is a melanotan nasal spray safer than injections?⌄
There is no evidence that it is. Nasal sprays are equally unapproved and unverified, and a 2025 case report described a melanoma inside the mouth of a young woman who used a melanotan II nasal spray for tanning.
Can I use melanotan II with my supplements or medicines?⌄
No interaction studies with supplements or medicines exist, so nothing is known about combining it with them. Ask a doctor or pharmacist to review your full list.
What should I do if I have used it and feel unwell?⌄
Get emergency care for an erection lasting more than 4 hours, a severe headache, confusion, vision changes, seizures, chest pain, a racing heart, severe muscle pain or dark urine. Tell the doctors what you injected or sprayed and bring the product if you can.
References by claim
erections in men with erectile dysfunction
skin darkening (tanning)
Dorr et al., 1996 · PubMed (1996) link
Safety
Hjuler et al., 2014 · PubMed (2014) link
Ong et al., 2012 · PubMed (2012) link
Yassin Alsabbagh et al., 2025 · PubMed (2025) link
Schulze et al., 2014 · PubMed (2014) link
FDA: Certain bulk drug substances for use in compounding that may present significant safety risks · FDA link
Nelson et al., 2012 · PubMed (2012) link
Peters et al., 2020 · PMC (2020) link
Dreyer et al., 2019 · PMC (2019) link
Kaski et al., 2013 · PubMed (2013) link
FDA: Early announcement, meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027) · FDA link
Track Melanotan II with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This compound is not approved by the FDA for human use and is not a dietary supplement. This page is an educational review of available research (much of it preclinical or early-stage), not a recommendation to use it. Consumer product quality is unregulated. Consult a qualified clinician.
